International trial of adjuvant therapy in high risk stage I non-squamous cell carcinoma identified by a 14-gene prognostic signature

Translational Lung Cancer Research

Volumn 2, Issue 3, 2013, Pages 222-225

  Kratz, Johannes R ^a   Mann, Michael J ^b   Jablons, David M ^b  

^a MASSACHUSETTS GENERAL HOSPITAL   (United States)

^b UCSF Thoracic Surgery   (United States)

Author keywords

Adjuvant therapy; Biomarker; Molecular; Non small cell lung cancer; Personalized therapy; Predictive; Prognostic; Signature

Indexed keywords

EID: 84959879629     PISSN: 22186751     EISSN: 22264477     Source Type: Journal    
DOI: 10.3978/j.issn.2218-6751.2013.05.01     Document Type: Review

References (12)

1. Goldstraw P, Ball D, Jett JR, et al. Non-small-cell lung cancer. Lancet 2011;378:1727-40.
2. Herbst RS, Heymach JV, Lippman SM. Lung cancer. N Engl J Med 2008;359:1367-80.
3. Jemal A, Siegel R, Xu J, et al. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277-300.
4. Ginsberg RJ, Rubinstein LV. Randomized trial of lobectomy versus limited resection for T1 N0 non-small cell lung cancer. Lung Cancer Study Group. Ann Thorac Surg 1995;60:615-22; discussion 622-3.
5. Subramanian J, Simon R. Gene expression-based prognostic signatures in lung cancer: ready for clinical use? J Natl Cancer Inst 2010;102:464-74.
6. Kratz JR, Jablons DM. Genomic prognostic models in early-stage lung cancer. Clin Lung Cancer 2009;10:151-7.
7. NCCN clinical practice guidelines in oncology non-small cell lung cancer 2012.
8. Pignon JP, Tribodet H, Scagliotti GV, et al. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group. J Clin Oncol 2008;26:3552-9.
9. Goldstraw P, Shepherd FA, Pass HI. The International Staging System for lung cancer. Am Soc Clin Oncol Ed Book 2009;29:462-8.
10. Kratz JR, He J, Van Den Eeden SK, et al. A practical molecular assay to predict survival in resected nonsquamous, non-small-cell lung cancer: development and international validation studies. Lancet 2012;379:823-32.
11. Kratz JR, Van den Eeden SK, He J, et al. A prognostic assay to identify patients at high risk of mortality despite small, node-negative lung tumors. JAMA 2012;308:1629-31.
12. Director's Challenge Consortium for the Molecular Classification of Lung Adenocarcinoma, Shedden K, Taylor JM, et al. Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med 2008;14:822-7.